Morepen Labs.

Morepen Laboratories Ltd Profit & Loss Statement

NSEBSE

₹54.52

(0.07%)

Apr 23, 2025|12:00:00 AM

Invest wise with Expert advice

QUICKLINKS FOR Morepen Laboratories Ltd

FINANCIALS

Profit & Loss Balance Sheet Cash Flow Ratios Results

ConsolidatedStandalone

GraphTable

Y/e 31 Mar( In .Cr)	Mar-2021	Mar-2020	Mar-2018	Mar-2017
Revenue	1,112.42	791.98	560.83	547.5
yoy growth (%)	40.45	41.21	2.43	21
Raw materials	-736.61	-521.08	-342.59	-335.73
As % of sales	66.21	65.79	61.08	61.32
Employee costs	-123.2	-98.07	-68.21	-60.79
As % of sales	11.07	12.38	12.16	11.1
Other costs	-140.23	-108.36	-89.74	-90.49
As % of sales (Other Cost)	12.6	13.68	16	16.52
Operating profit	112.37	64.46	60.26	60.48
OPM	10.1	8.13	10.74	11.04
Depreciation	-28.11	-34.43	-33.39	-33.56
Interest expense	-1.78	-1.96	-4.29	-7.47
Other income	11.77	9.41	3.54	3.71
Profit before tax	94.24	37.48	26.11	23.16
Taxes	0	-5.14	0	0
Tax rate	0	-13.73	0	0
Minorities and other	0	0	0	0
Adj. profit	94.24	32.33	26.11	23.16
Exceptional items	0	0	0	0
Net profit	94.24	32.33	26.11	23.16
yoy growth (%)	191.49	23.8	12.72	46.83
NPM	8.47	4.08	4.65	4.23

Morepen Labs. : related Articles

Morepen Labs Secures China’s NMPA Approval for Loratadine Export

1 Apr 2025|02:22 PM

With this approval, Morepen Laboratories aims to strengthen its presence in China, which is one of the world’s largest pharmaceutical markets.

Morepen Launches Empamore for Diabetes, Heart & Kidney Care

18 Mar 2025|01:30 PM

Developed from scratch, this drug offers an inexpensive and superior alternative to current treatments, making it accessible to hundreds of millions of patients.